...And while these medications have been effective in their own right, there has been limitations. And today, patients continue to be symptomatic even with this treatment. And so ensifentrine, which is a novel mechanism as a PDE3, PDE4 inhibitor, as you'll see today, has incredible promise and opportunity for the treatment of COPD and, ultimately, we believe, will actually change the treatment paradigm for COPD. You all know that COPD is actually a progressive disease, which there is no cure. Patients continue to be symptomatic and progress through their disease. These characteristics of this disease is, of course, shortness of breath, cough, and infections. And clearly, the hallmark of treatment is really to help alleviate these symptoms and make patients feel better, breathe easier, and be able to function, and also to prevent exacerbations, which is also something that, in COPD, we try to avoid because that is ultimately where patients continue to lose lung function with additional exacerbations....
